ALACHUA, Fla.--(BUSINESS WIRE)--Nanotherapeutics, Inc., a privately held specialty biopharmaceutical company, announced that NanoBUP™ Oral Buprenorphine / Naloxone Capsule, for treating opiate addiction, demonstrated strong oral absorption in a Phase Ia clinical trial. The 2 x 2mg capsule achieved significant oral bioavailability of 60 to 70 percent, in comparison to sublingual administration of buprenorphine/naloxone at a similar dose, as reported in published scientific reports. NanoBUP™ is a stable, swallowed capsule containing buprenorphine / naloxone developed with the Company’s proprietary NanoDRY® particle delivery system. The product is an immediate release capsule that allows buprenorphine to be absorbed more efficiently from the upper gastrointestinal tract, offering an improved route of administration over currently available formulations.
